Arcadia Investment Management Corp MI Invests $72,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Arcadia Investment Management Corp MI bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,155 shares of the company’s stock, valued at approximately $72,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Hager Investment Management Services LLC acquired a new position in shares of TransMedics Group in the 4th quarter valued at about $33,000. Sachetta LLC purchased a new stake in TransMedics Group during the 4th quarter worth $40,000. Quarry LP raised its position in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares during the period. National Bank of Canada FI lifted its stake in shares of TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after buying an additional 316 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

TMDX stock opened at $71.95 on Friday. The stock’s 50 day simple moving average is $66.47 and its 200 day simple moving average is $105.05. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a market cap of $2.41 billion, a P/E ratio of 76.54 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

Insiders Place Their Bets

In related news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This represents a 4.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on TMDX shares. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Piper Sandler decreased their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. TD Cowen lowered their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.